At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 71 enrolled
Drug / intervention
Ruxolitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib and Prednisone or methylprednisolone for Graft-versus-host Disease (GVHD). Completed, enrolled 71 participants across 38 sites.
Detailed Summary
The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft-versus-host Disease (GVHD)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionJan 2018
Study CompletionAug 2019
TodayJul 2026
First PostedNov 3, 2016
Enrollment StartDec 30, 2016
Primary CompletionJan 31, 2018
Study CompletionAug 14, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.7 years ago
Interventions
Ruxolitinibdrug
Prednisone or methylprednisolonedrug
Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.